Aldo-keto reductases and bioactivation/detoxication

Annual Review of Pharmacology and Toxicology

Volumn 47, Issue , 2007, Pages 263-292

  Jin, Yi ^a   Penning, Trevor M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cancer chemotherapeutics; CNS acting drugs; Gene regulation; Hormone replacement therapeutics; Polycyclic aromatic hydrocarbons; Reactive aldehydes

Indexed keywords

AFLATOXIN; ALDEHYDE DERIVATIVE; ALDEHYDE REDUCTASE; ALDO KETO REDUCTASE; ANTHRACYCLINE ANTIBIOTIC AGENT; CARCINOGEN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; ENZYME INHIBITOR; EPIRUBICIN; HALOPERIDOL; INDOMETACIN; NALTREXONE; NICOTINE; NONSTEROID ANTIINFLAMMATORY AGENT; OXIDOREDUCTASE; POLYCYCLIC AROMATIC HYDROCARBON; TIBOLONE; UNCLASSIFIED DRUG;

ANTIOXIDANT RESPONSIVE ELEMENT; CARCINOGENESIS; CARDIOTOXICITY; DETOXIFICATION; DRUG ACTIVATION; DRUG DETOXIFICATION; DRUG METABOLISM; ENZYME MECHANISM; ENZYME STRUCTURE; GENE CONTROL; GENETIC POLYMORPHISM; HEMORRHAGIC CYSTITIS; HUMAN; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; TISSUE DISTRIBUTION;

ALCOHOL OXIDOREDUCTASES; ALDEHYDES; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOGENS; CENTRAL NERVOUS SYSTEM AGENTS; GENE EXPRESSION REGULATION; HORMONES; HUMANS; POLYCYCLIC HYDROCARBONS, AROMATIC;

NICOTIANA TABACUM;

EID: 33847021147     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.47.120505.105337     Document Type: Review

References (126)

1. Hyndman DR, Bauman DR, Heredia VV, Penning TM. 2003. The aldo-keto reductase superfamily homepage. Chem.-Biol. Inter. 143-144:621-31
2. Jez JM, Bennett MJ, Schlegel BP, Lewis M, Penning TM. 1997. Comparative anatomy of the aldo-keto reductase superfamily. Biochem. J. 326:625-36
3. Flynn GT. 1982. Monomeric NADPH-dependent oxidoreductases with multifunctional potential. Biochem. Pharmacol. 31:2705-12
4. Penning TM. 2004. Introduction and overview of the aldo-keto reductase superfamily. See Ref. 124, pp. 3-20
5. Bohren KM, Bullock B, Wermuth B, Gabbay KH. 1989. The aldo-keto reductase superfamily. cDNAs and deduced amino acid sequences of human aldehyde and aldose reductases. J. Biol. Chem. 264:9547-51
6. Askonas LJ, Ricigliano JW, Penning TM. 1991. The kinetic mechanism catalyzed by homogeneous rat liver 3α-hydroxysteroid dehydrogenase. Evidence for binary and ternary dead-end complexes containing nonsteroidal antiinflammatory drugs. Biochem. J. 278:835-41
7. Neuhauser W, Haltrich D, Kulbe KD, Nidetzky B. 1997. NAD(P)H-dependent aldose reductase from the xylose-assimilating yeast Candida tennis. Isolation, characterization and biochemical properties of the enzyme. Biochem. J. 326(Pt. 3):683-92
8. Trauger JW, Jiang A, Stearns BA, LoGrasso PV. 2002. Kinetics of allopregnanolone formation catalyzed by human 3α-hydroxysteroid dehydrogenase type III (AKR1C2). Biochemistry 41:13451-59
9. Schlegel BP, Jez JM, Penning TM. 1998. Mutagenesis of 3α-hydroxysteroid dehydrogenase reveals a "push-pull" mechanism for proton transfer in aldoketo reductases. Biochemistry 37:3538-48
10. Penning TM. 1999. Molecular determinants of steroid recognition and catalysis in aldo-keto reductases. Lessons from 3α-hydroxysteroid dehydrogenase. J. Steroid Biochem. Mol. Biol. 69:211-25
11. Penning TM, Jin Y, Steckelbroeck S, Lanisnik Rizner T, Lewis M. 2004. Structure-function of human 3α-hydroxysteroid dehydrogenases: genes and proteins. Mol. Cell Endocrinol. 215:63-72
12. Grimshaw CE, Bohren KM, Lai CJ, Gabbay KH. 1995. Human aldose reductase: rate constants for a mechanism including interconversion of ternary complexes by recombinant wild-type enzyme. Biochemistry 34:14356-65
13. Nidetzky B, Klimacek M, Mayr P. 2001. Transient-state and steady-state kinetic studies of the mechanism of NADH-dependent aldehyde reduction catalyzed by xylose reductase from the yeast Candida tennis. Biochemistry 40:10371-81
14. Heredia VV, Penning TM. 2004. Dissection of the physiological interconversion of 5α-DHT and 3α-diol by rat 3α-HSD via transient kinetics shows that the chemical step is rate-determining: effect of mutating cofactor and substrate-binding pocket residues on catalysis. Biochemistry 43:12028-37
15. Flynn TG, Green NC, Bhatia MB, El-Kabbani O. 1995. Structure and mechanism of aldehyde reductase. Adv. Exp. Med. Biol. 372:193-201
16. Bohren KM, Grimshaw CE, Gabbay KH. 1992. Catalytic effectiveness of human aldose reductase. Critical role of the C-terminal domain. J. Biol. Chem. 267:20965-70
17. Crosas B, Hyndman D, Gallego O, Matras S, Pares X, Flynn TG. 2003. Human aldose reductase and human small intestine aldose reductase are efficient retinal reductases: consequences for retinoid metabolism. Biochem. J. 373:973-79
18. Burczynski ME, Harvey RG, Penning TM. 1998. Expression and characterization of four recombinant human dihydrodiol dehydrogenase isoforms: oxidation of trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene to the activated o-quinone metabolite benzo[a]pyrene-7,8-dione. Biochemistry 37:6781-90
19. Stolz A, Hammond L, Lou H, Takikawa H, Ronk M, Shively JE. 1993. cDNA cloning and expression of the human hepatic bile acid-binding protein. A member of the monomeric reductase gene family. J. Biol. Chem. 268:10448-57
20. + channel β-1 gene and functional expression of the β-2 gene product. FEBS Lett. 350:32-36
21. Ireland LS, Harrison DJ, Neal GE, Hayes JD. 1998. Molecular cloning, expression and catalytic activity of a human AKR7 member of the aldo-keto reductase superfamily: evidence that the major 2-carboxybenzaldehyde reductase from human liver is a homologue of rat aflatoxin B1-aldehyde reductase. Biochem. J. 332:21-34
22. Knight L, Primiano T, Groopman JD, Kensler TW, Sutter TR. 1999. cDNA cloning, expression and activity of a second human aflatoxin B1-metabolizing member of the aldo-keto reductase superfamily, AKR7A3. Carcinogenesis 20:1215-23
23. 4-3-oxosteroid 5β-reductase and substrate specificity of the expressed enzyme. Eur. J. Biochem. 219:357-63
24. Penning TM, Burczynski ME, Jez JM, Hung CF, Lin HK, et al. 2000. Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem. J. 351:67-77
25. Ji Q, Chang L, VanDenBreg D, Stanczyk FZ, Stolz A. 2003. Selective reduction of AKR1C2 in prostate cancer and its role in DHT metabolism. Prostate 54:275-89
26. Pelletier G, Luu-The V, Tetu B, Labrie F. 1999. Immunocytochemical localization of type 5 17β-hydroxysteroid dehydrogenase in human reproductive tissues. J. Histochem. Cytochem. 47:731-37
27. Ji Q, Aoyama C, Nica YD, Liu PI, Chen PK, et al. 2004. Selective loss of AKR1C1 and AKR1C2 in breast cancer and their potential effect on progesterone signaling. Cancer Res. 64:7610-17
28. Lin HK, Steckelbroeck S, Fung KM, Jones AN, Penning TM. 2004. Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3α-hydroxysteroid dehydrogenase/type 5 17β-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate. Steroids 69:795-801
29. Smithgall TE, Penning TM. 1988. Electrophoretic and immunochemical characterization of 3α-hydroxysteroid/dihydrodiol dehydrogenases of rat tissues. Biochem. J. 254:715-21
30. Oka M, Kato N. 2001. Aldose reductase inhibitors. J. Enzyme. Inhib. 16:465-73
31. El-Kabbani O, Ruiz F, Darmanin C, Chung RP. 2004. Aldose reductase structures: implications for mechanism and inhibition. Cell. Mol. Life Sci. 61:750-62
32. Sato S, Kador PF. 1990. Inhibition of aldehyde reductase by aldose reductase inhibitors. Biochem. Pharmacol. 40:1033-42
33. +-linked oxidoreductase from rat liver cytosol by steroidal and nonsteroidal anti-inflammatory agents and by prostaglandins. Proc. Natl. Acad. Sci. USA 80:4504-8
34. Steckelbroeck S, Jin Y, Gopishetty S, Oyesanmi B, Penning TM. 2003. Human cytosolic 3α-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3β-hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action. J. Biol. Chem. 279:10784-95
35. Deyashiki Y, Tamada Y, Miyabe Y, Nakanishi M, Matsuura K, Hara A. 1995. Expression and kinetic properties of a recombinant 3α-hydroxysteroid/ dihydrodiol dehydrogenase isoenzyme of human liver. J. Biochem. 118:285-90
36. Rosemond MJC, Walsh JS. 2004. Human carbonyl reduction pathways and a strategy for their study in vitro. Drug Metab. Rev. 36:335-61
37. 5(10)-3-ketosteroid. Mol. Pharmacol. 66:1702-11
38. Steckelbroeck S, Oyesanmi B, Jin Y, Lee SH, Kloosterboer HJ, Penning TM. 2006. Tibolone metabolism in human liver is catalyzed by 3α/3β- hydroxysteroid dehydrogenase activities of the four isoforms of the aldo-keto reductase (AKR)1C subfamily. J. Pharmacol. Exp. Ther. 316:1300-9
39. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. 2004. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56:185-229
40. Ohara H, Miyabe Y, Deyashiki Y, Matsuura K, Hara A. 1995. Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver. Biochem. Pharmacol. 50:221-27
41. Behnia K, Boroujerdi M. 1999. Inhibition of aldo-keto reductases by phenobarbital alters metabolism, pharmacokinetics and toxicity of doxorubicin in rats. J. Pharm. Pharmacol. 51:1275-82
42. Salvatorelli E, Guarnieri S, Menna P, Liberi G, Calafiore AM, et al. 2006. Defective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart: relative importance of vesicular sequestration and impaired efficiency of electron addition. J. Biol. Chem. 281:10990-1001
43. Ax W, Soldan M, Koch L, Maser E. 2000. Development of daunorubicin resistance in tumor cells by induction of carbonyl reduction. Biochem. Pharmacol. 59:293-300
44. Lee EK, Regenold WT, Shapiro P. 2002. Inhibition of aldose reductase enhances HeLa cell sensitivity to chemotherapeutic drugs and involves activation of extracellular signal-regulated kinases. Anticancer Drugs 13:859-68
45. Kolb NS, Hunsaker LA, Vander Jagt DL. 1994. Aldose reductase-catalyzed reduction of acrolein: implications in cyclophosphamide toxicity. Mol. Pharmacol. 45:797-801
46. Deng HB, Parekh HK, Chow KC, Simpkins H. 2002. Increased expression of dihydrodiol dehydrogenase induces resistance to cis-platin in human ovarian carcinoma cells. J. Biol. Chem. 277:15035-43
47. Chen YJ, Yuan CC, Chow KC, Wang PH, Lai CR, et al. 2005. Overexpression of dihydrodiol dehydrogenase is associated with cis-platin-based chemotherapy resistance in ovarian cancer patients. Gynecol. Oncol. 97:110-17
48. Porter SJ, Somogyi AA, White JM. 2000. Kinetics and inhibition of the formation of 6β-naltrexol from naltrexone in human liver cytosol. Br. J. Clin. Pharmacol. 50:465-71
49. Breyer-Pfaff U, Nill K. 2004. Carbonyl reduction of naltrexone and dolasetron by oxidoreductases isolated from human liver cytosol. J. Pharm. Pharmacol. 56:1601-6
50. Breyer-Pfaff U, Nill K. 2000. High-affinity stereoselective reduction of the enantiomers of ketotifen and of ketonic nortriptyline metabolites by aldo-keto reductases from human liver. Biochem. Pharmacol. 59:249-60
51. Cavalieri EL, Rogan EG. 1995. Central role of radical cations in metabolic activation of polycyclic aromatic hydrocarbons. Xenobiotica 25:677-88
52. Conney AH. 1982. Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons. G.H.A. Clowes Memorial Lecture. Cancer. Res. 42:4875-17
53. Penning TM, Burczynski ME, Hung CF, McCoull KD, Palackal NT, Tsuruda LS. 1999. Dihydrodiol dehydrogenases and polycyclic aromatic hydrocarbon activation: generation of reactive and redox-active o-quinones. Chem. Res. Toxicol. 12:1-18
54. Smithgall TE, Harvey RG, Penning TM. 1986. Regio- and stereospecificity of homogeneous 3α-hydroxysteroid-dihydrodiol dehydrogenase for trans-dihydrodiol metabolites of polycyclic aromatic hydrocarbons. J. Biol. Chem. 261:6184-91
55. Smithgall TE, Harvey RG, Penning TM. 1988. Spectroscopic identification of ortho-quinones as the products of polycyclic aromatic trans-dihydrodiol oxidation catalyzed by dihydrodiol dehydrogenase. A potential route of proximate carcinogen metabolism. J. Biol. Chem. 263:1814-20
56. Penning TM, Ohnishi ST, Ohnishi T, Harvey RG. 1996. Generation of reactive oxygen species during the enzymatic oxidation of polycyclic aromatic hydrocarbon trans-dihydrodiols catalyzed by dihydrodiol dehydrogenase. Chem. Res. Toxicol. 9:84-92
57. Palackal NT, Burczynski ME, Harvey RG, Penning TM. 2001. The ubiquitous aldehyde reductase (AKR1A1) oxidizes proximate carcinogen trans-dihydrodiols to o-quinones: potential role in polycyclic aromatic hydrocarbon activation. Biochemistry 40:10901-10
58. Palackal NT, Lee SH, Harvey RG, Blair IA, Penning TM. 2002. Activation of polycyclic aromatic hydrocarbon trans-dihydrodiol proximate carcinogens by human aldo-keto reductase (AKR1C) enzymes and their functional overexpression in human lung carcinoma cells. J. Biol. Chem. 277:24799-808
59. McCoull KD, Rindgen D, Blair IA, Penning TM. 1999. Synthesis and characterization of polycyclic aromatic hydrocarbon o-quinone depurinating N7-guanine adducts. Chem. Res. Toxicol. 12:237-46
60. Balu N, Padgett WT, Lambert GR, Swank AE, Richard AM, Nesnow S. 2004. Identification and characterization of novel stable deoxyguanosine and deoxyadenosine adducts of benzo[a]pyrene-7,8-quinone from reactions at physiological pH. Chem. Res. Toxicol. 17:827-38
61. Murty VS, Penning TM. 1992. Polycyclic aromatic hydrocarbon (PAH) ortho-quinone conjugate chemistry: kinetics of thiol addition to PAH ortho-quinones and structures of thiol-ether adducts of naphthalene-1,2-dione. Chem.-Biol. Inter. 84:169-88
62. Murty VS, Penning TM. 1992. Characterization of mercapturic acid and glutathionyl conjugates of benzo[a]pyrene-7,8-dione by two dimensional NMR. Bioconj. Chem. 3:218-24
63. Park JH, Gopishetty S, Szewczuk LM, Troxel AB, Harvey RG, Penning TM. 2005. Formation of 8-oxo-7,8-dihydro-2′-deoxygaunosine (8-oxo-dGuo) by PAH o-quinones: involvement of reactive oxygen species and copper (II)/copper (I) redox cycling. Chem. Res. Toxicol. 18:1026-37
64. Rushmore TH, Morton MR, Pickett CB. 1991. The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. J. Biol. Chem. 266:11632-39
65. Burczynski ME, Sridhar GR, Palackal NT, Penning TM. 2001. The reactive oxygen species and Michael acceptor-inducible human aldo-keto-reductase AKR1C1 reduces the α,β-unsaturated aldehyde 4-hydroxy-2-nonenal to 1,4-dihydroxy-2-nonene. J. Biol. Chem. 276:2890-97
66. Cerutti PA. 1985. Prooxidant states and tumor promotion. Science 227:375-81
67. Du MQ, Carmichael PL, Phillips DH. 1994. Induction of activating mutations in the human c-Ha-ras-1 proto-oncogene by oxygen free radicals. Mol. Carcinog. 11:170-75
68. Heyworth P, Knaus UG, Settleman J, Curnutte JT, Bokoch GM. 1993. Regulation of NADPH oxidase activity by Rac GTPase activating protein(s). Mol. Biol. Cell 11:1217-23
69. Burczynski ME, Penning TM. 2000. Genotoxic polycyclic aromatic hydrocarbon o-quinones generated by aldo-keto reductases induce CYP1A1 via nuclear translocation of the aryl hydrocarbon receptor. Cancer Res. 60:908-15
70. Jiang H, Vudathala DK, Blair IA, Penning TM. 2006. Competing roles of aldoketo reductase 1A1 and cytochrome P4501Bl in benzo[a]pyrene-7,8-diol activation in human bronchoalveolar H358 cells: role of AKRs in P4501B1 induction. Chem. Res. Toxicol. 19:68-78
71. Itoh K, Chiba T, Takahashi S, Ishii T, Igarrashi K, et al. 1997. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through the antioxidant response element. Biochem. Biophys. Res. Commun. 236:313-22
72. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, et al. 1999. Keap-1 represses nuclear activation of the antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 13:76-86
73. Hsu NY, Ho HC, Chow KC, Lin TY, Shih CS, et al. 2001. Overexpression of dihydrodiol dehydrogenase as a prognostic marker of nonsmall cell lung cancer. Cancer Res. 61:2727-31
74. Fukumoto S, Yamauchi N, Moriguchi H, Hippo Y, Watanabe A, et al. 2005. Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' nonsmall cell lung carcinomas. Clin. Cancer Res. 11:1776-85
75. Jiang H, Shen YM, Quinn AM, Penning TM. 2005. Competing roles of cytochrome P450 1A1/1B1 and aldo-keto reductase 1A1 in the metabolic activation of (±)7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene in human bronchoalveolar cell extracts. Chem. Res. Toxicol. 18:365-74
76. Hecht SS. 1998. Biochemistry, biology and carcinogenicity of tobacco-specific N-nitrosamines. Chem. Res. Toxicol. 11:560-603
77. Maser E, Breyer-Pfaff U. 2004. Competing roles of reductases in the detoxification of the tobacco-specific nitrosamine ketone NKK. See Ref. 124, pp. 67-82
78. Guengerich FP, Johnson WW. 1999. Kinetics of hydrolysis and reaction of aflatoxin B1 exo-8,9-epoxide and relevance to toxicity and detoxication. Drug. Metab. Rev. 31:141-58
79. Guengerich FP, Arneson KO, Williams KM, Deng Z, Harris TM. 2002. Reaction of aflatoxin B1 oxidation products with lysine. Chem. Res. Toxicol. 15:780-92
80. Ellis E, Judah DJ, Neal GE, Hayes JD. 1993. Anethoxyquin-inducible aldehyde reductase from rat liver that metabolizes aflatoxin B1 defines a subfamily of aldo-keto reductases. Proc. Natl. Acad. Sci. USA 90:10350-54
81. Kelly V, O'Connor T, Ellis EM, Ireland LS, Slattery CM, et al. 2004. Aflatoxin aldehyde reductases. See Ref. 124, pp. 155-70
82. O'Connor T, Ireland LS, Harrison DJ, Hayes JD. 1999. Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members. Biochem. J. 343:487-504
83. International Agency for Research on Cancer. 2002. IARC Monographs on the evaluation of the carcinogenic risk of chemicals to humans. Int. Agency Res. Cancer, Lyons, France
84. Esterbauer H, Schauer RJ, Zollner H. 1991. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 11:81-128
85. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y. 1996. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl. Acad. Sci. USA 93:2696-701
86. Zarkovic K. 2003. 4-Hydroxynonenal and neurodegenerative diseases. Mol. Aspects Med. 24:293-303
87. Esterbauer H. 1993. Cytotoxicity and genotoxicity of lipid-oxidation products. Am. J. Clin. Nutr. 57:779S-85
88. Rindgen D, Nakajima M, Wehrli S, Xu K, Blair IA. 1999. Covalent modifications to 2′-deoxygaunosine by 4-oxo-2-nonenal a novel product of lipid peroxidation. Chem. Res. Toxicol. 12:1195-204
89. Lee SH, Rindgen D, Bible RHJ, Hajdu E, Blair IA. 2000. Characterization of 2′-deoxyadenosine adducts derived from 4-oxo-nonenal, a novel product of lipid peroxidation. Chem. Res. Toxicol. 13:565-74
90. Lee HS, Oe T, Blair IA. 2001. Vitamin C-induced decomposition of lipid hydroperoxides to endogenous genotoxins. Science 292:2083-86
91. Ramana KV, Dixit BL, Srivastava S, Balendiran GK, Srivastava SK, Bhatanagar A. 2000. Selective recognition of glutathiolated aldehydes by aldose reductase. Biochemistry 39:12172-80
92. Srivastava S, Conklin DJ, Liu SQ, Prakash N, Boor PJ, et al. 2001. Identification of biochemical pathways for the metabolism of oxidized low-density lipoprotein derived aldehyde-4-hydroxy-trans-2-nonenal in vascular smooth muscle cells. Atheroscelrosis 158:339-50
93. Cao D, Fan ST, Chung SS. 1998. Identification and characterization of a novel human aldose reductase-like gene. J. Biol. Chem. 273:11429-35
94. Rizner T, Lin HK, Peehl DM, Steckelbroeck S, Bauman DR, Penning TM. 2003. Human type 3 3α-hydroxysteroid dehydrogenase (AKR1C2) and androgen metabolism in prostate cells. Endocrinology 144:2922-32
95. Fung KM, Samara ENS, Wong C, Metwalli A, Krlin R, et al. 2006. Increased expression of type 2 3α-hydroxysteroid dehydrogenase/type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocr. Related Cancer 13:169-80
96. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, et al. 2006. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 66:2815-25
97. Keenan C, Ghaffar S, Grant AW, Hinshelwood A, Li D, et al. 2006. Succinic semialdehyde reductases: contribution to γ-hydroxybutyrate catabolism and subcellular localization. In Enzymology and Molecular Biology of Carbonyl Metabolism, ed. H Wiener, B Plapp, R Lindahl, E Maser. West Lafayette, IN: Purdue Univ. Press
98. Nishinaka T, Yabe-Nishimura C. 2005. Transcription factor Nrf2 regulates promoter activity of mouse aldose reductase (AKR1B3) gene. J. Pharmacol. Sci. 97:43-51
99. Ko B, Ruepp B, Bohren KM, Gabbay K, Chung S. 1997. Identification and characterization of multiple osmotic response sequences in the human aldose reductase gene. J. Biol. Chem. 272:16431-37
100. Lopez RC, Aranburu J, Rakeman AS, Rao A. 1999. NFAT5, a constitutively nuclear NFAT protein that does not cooperate with Fos and Jun. Proc. Natl. Acad. Sci. USA 96:7214-19
101. Miyakawa H, Woo SK, Dahl SC, Handler JS, Kwon HM. 1999. Tonicity-responsive enhancer binding protein, a rel-like protein that stimulates transcription in response to hypertonicity. Proc. Natl. Acad. Sci. USA 96:2538-42
102. Abate C, Luk D, Gagne E, Roeder RG, Curran T. 1990. Fos and jun cooperate in transcriptional regulation via heterologous activation domains. Mol. Cell. Biol. 10:5532-35
103. Karin M. 1995. The regulation of AP-1 activity by mitogen activated protein kinases. J. Biol. Chem. 270:16483-86
104. Abate C, Patel L, Ruascher IFJ, Curran T. 1990. Redox-regulation of fos and jun DNA-binding activity in vitro. Science 249:1157-61
105. Angel P, Karin M. 1991. The role of jun and fos and the AP-1 complex in cell proliferation and transformation. Biochim. Biophys. Acta 1072:129-57
106. Xanthoudakis S, Miao G, Wang F, Pan YC, Curran T. 1992. Redox activation of fos-jun DNA binding activity is regulated by a DNA repair enzyme. EMBO J. 11:3323-35
107. Xanthoudakis S, Miao G, Curran T. 1994. The redox and DNA repair activties of Ref-1 are encoded by nonoverlapping domains. Proc. Natl. Acad. Sci. USA 91:23-27
108. Burczynski ME, Lin HK, Penning TM. 1999. Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenases. Cancer Res. 59:607-14
109. Lou H, Du S, Ji Q, Stolz A. 2006. Induction of AKR1C2 by phase II inducers: identification of a distal consensus antioxidant response element (ARE) regulated by Nrf2. Mol. Pharmacol. 69:1662-72
110. Dinkova-Kostova AT, Holtzclaw WD, Kensler TW. 2005. The role of Keap1 in cellular protective responses. Chem. Res. Toxicol. 18:1779-91
111. Ciaccio P, Shen H, Jaiswal A, Lyttle M, Tew K. 1995. Modulation of detoxification gene expression in human colon HT29 cells by glutathione-S- transferase inhibitors. Mol. Pharmacol. 48:639-47
112. Ciaccio P, Jaiswal A, Tew K. 1994. Regulation of human dihydrodiol dehydrogenases by Michael acceptor xenobiotics. J. Biol. Chem. 269:15558-62
113. Bauman DR, Rudnick SI, Szewczuk LM, Jin Y, Gopishetty S, Penning TM. 2005. Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: potential anti-neoplastic agents that work independently of cyclooxygenase isozymes. Mol. Pharmacol. 67:60-68
114. Chung SS, Ho EC, Lam KS, Chung SK. 2003. Contribution of polyol pathway to diabetes-induced oxidative stress. J. Am. Soc. Nephrol. 14:S233-36
115. Srivastava SK, Ramana KV, Bhatnagar A. 2005. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr. Rev. 26:380-92
116. Demaine AG. 2003. Polymorphisms of the aldose reductase gene and susceptibility to diabetic microvascular complications. Curr. Med. Chem. 10:1389-98
117. Chung SS, Chung SK. 2003. Genetic analysis of aldose reductase in diabetic complications. Curr. Med. Chem. 10:1375-87
118. Donaghue KC, Margan SH, Chan AK, Holloway B, Silink M, et al. 2005. The association of aldose reductase gene (AKR1B1) polymorphisms with diabetic neuropathy in adolescents. Diabet. Med. 22:1315-20
119. Petrovic MG, Peterlin B, Hawlina M, Petrovic D. 2005. Aldose reductase (AC)n gene polymorphism and susceptibility to diabetic retinopathy in Type 2 diabetes in Caucasians. J. Diabet. Complica. 19:70-73
120. Sivenius K, Niskanen L, Voutilainen-Kaunisto R, Laakso M, Uusitupa M. 2004. Aldose reductase gene polymorphisms and susceptibility to microvascular complications in Type 2 diabetes. Diabet. Med. 21:1325-33
121. Lan Q, Mumford JL, Shen M, Demarini DM, Bonner MR, et al. 2004. Oxidative damage-related genes AKR1C3 and OGG1 modulate risks for lung cancer due to exposure to PAH-rich coal combustion emissions. Carcinogenesis 25:2177-81
122. Kume T, Iwasa H, Shiraishi H, Yokoi T, Nagashima K, et al. 1999. Characterization of a novel variant (S145C/L311V) of 3α-hydroxysteroid/ dihydrodiol dehydrogenase in human liver. Pharmacogenetics 9:763-71
123. Lord SJ, Mack WJ, Van Den Berg D, Pike MC, Ingles SA, et al. 2005. Polymorphisms in genes involved in estrogen and progesterone metabolism and mammographic density changes in women randomized to postmenopausal hormone therapy: results from a pilot study. Breast Canc. Res. 7:R336-44
124. Penning TM, Petrash JM. 2004. Aldo-Keto Reductases and Toxicant Metabolism. Washington, DC: Am. Chem. Soc.
125. http://www.med.upenn.edu/akr/
126. http://www.med.upenn.edu/ceet/